From: A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response
Optimal two stage design
Optimum design
First stage sample size (n1)
20
 a1
6
 b1
12
Maximum sample size (n)
40
 b2
17